Encouraging early results of a major 10,000 patient NHS lung cancer screening trial using EarlyCDT®-Lung have been announced, attracting attention across UK national news. ITN news and The Times highlighted new positive results from the National Health Service (NHS) Scotland ECLS study.
The study is the largest randomised trial for the early detection of lung cancer using biomarkers ever conducted. The initial results were presented in full by Professor Frank Sullivan, Chief Investigator of the ECLS study, at the IASLC’s 16th World Conference on Lung Cancer, on 7th September. In summary, the trial showed the cancer pick up rate to be considerably better than the stated test performance.
Geoffrey Hamilton-Fairly, CEO of Oncimmune, said: “If these results continue, it will further underpin the rationale of the ECLS study – namely that screening with EarlyCDT-Lung can be effective for the early detection of lung cancer, helping save lives and money for healthcare providers.”
EarlyCDT-Lung is a simple blood test which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer.